Why the study?
What are the potential applications of DX-9065a in the management of patients with cardiovascular disease?
What are the potential applications of DX-9065a in the management of patients with cardiovascular disease?
DX-9065a represents a novel class of direct factor Xa inhibitors with potential therapeutic applications for atherothrombotic cardiovascular diseases.
Does not support clinical use; leaves open further development of direct factor Xa antagonists.
The development of anticoagulants for treating patients with atherothrombotic disorders of the arterial circulatory system has focused, either directly or indirectly, on thrombin - a pleuripotential effector enzyme with prothrombotic and proinflammatory properties. The pivotal role of factor (f) Xa in thrombin generation, coupled with its direct cellular effects and widely recognized limitations of currently available anticoagulants, has led to the development of pharmacologic inhibitors of this important protease. The following review focuses on DX-9065a - first in a class of direct, selective and reversible fXa antagonists - and its potential applications in the management of patients with cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: